title: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
abstract: OBJECTIVE
  To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement.
  
  
  METHODS
  From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles.
  
  
  RESULTS
  Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2).
  
  
  CONCLUSIONS
  This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
authors: Institute of Hematology and Oncology L. & A. Seràgnoli, University of Bologna, Bologna, Italy. plzinzo@med.unibo.it
authors: Pier Luigi
authors: PL
authors: Zinzani
authors: Gerardo
authors: G
authors: Musuraca
authors: Monica
authors: M
authors: Tani
authors: Vittorio
authors: V
authors: Stefoni
authors: Enrica
authors: E
authors: Marchi
authors: Mariapaola
authors: M
authors: Fina
authors: Cinzia
authors: C
authors: Pellegrini
authors: Lapo
authors: L
authors: Alinari
authors: Enrico
authors: E
authors: Derenzini
authors: Antonio
authors: A
authors: de Vivo
authors: Elena
authors: E
authors: Sabattini
authors: Stefano
authors: S
authors: Pileri
authors: Michele
authors: M
authors: Baccarani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000494:pharmacology*; D011719:Pyrazines / Q000008:administration & dosage*; D012008:Recurrence; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib